Harold V. Meyers, Ph.D.

Dr. Meyers has 18 years of pharmaceutical drug discovery experience at several highly successful startup companies. He was most recently the Director of Chemistry at Suntory Pharmaceutical Research Laboratories (later named Daiamed), where he led a team of chemists in the protein structure guided design of serine protease and kinase inhibitors, as well as modulators of nuclear hormone receptors and other target classes. Prior to that, he was Senior Director, Chemistry and Drug Discovery at New Chemical Entities (NCE), a natural products drug discovery company subsequently acquired by Albany Molecular. As Head, Cambridge Research at Sphinx Pharmaceuticals, Dr. Meyers spearheaded the development of combinatorial chemistries and enabling technologies that contributed to the acquisition of Sphinx by Eli Lilly. Prior to joining Sphinx, he was one of the first scientists at Vertex Pharmaceuticals, where he worked on the rational design of small molecule inhibitors. Dr. Meyers received a B.S. degree in Chemistry from Colorado State University, a Ph.D. in Organic Chemistry from Yale University, and completed his postdoctoral studies at Columbia University.